echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > ViiV's once-in-two-month long-acting injection cabottegravir, used to prevent HIV, has been named the FDA's breakthrough therapy

    ViiV's once-in-two-month long-acting injection cabottegravir, used to prevent HIV, has been named the FDA's breakthrough therapy

    • Last Update: 2020-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ViiV Healthcare, a subsidiary of GlaxoSmithKline, announced that its february long-acting injection Cabotegravir, which prevents HIV, has been named the U.S. Food and Drug Administration's (FDA) Breakthrough Therapy (BTD).
    BTD is based on the results of the IIb/III HPTN 083 trial, which compared cabogravir with the standard pre-exposure prophylactic drug (PrEP) for HIV - the daily oral drug Truvada (FTC/TDF, entourage/ginolfovir, 200mg/300mg tablets) for HIV prevention.
    results showed that cabotegravir was 66 percent more effective at preventing HIV than daily oral FTC/TDF tablets, 0.41 percent in cabotegravir and 1.22 percent in FTC/TDF.
    : According to ViiV, about 38 million people are currently living with HIV, with 1.7 million new cases reported by the end of 2019.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.